Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 13:48:10 2024-05-10 EDT 		5-day change 1st Jan Change
4.395 USD -1.90% Intraday chart for Vistagen Therapeutics, Inc. -2.44% -14.59%
04-25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI
04-01 Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 54.55 21.65 305.3 256.1 27.35 121.1 - -
Enterprise Value (EV) 1 54.55 21.65 305.3 256.1 27.35 6.973 60.47 121.1
P/E ratio -1.42 x -0.88 x -4.35 x -4.96 x -0.44 x -2.8 x -2.29 x -2.89 x
Yield - - - - - - - -
Capitalization / Revenue - - 280 x 231 x -120 x 113 x 605 x -
EV / Revenue - - 280 x 231 x -120 x 6.54 x 302 x -
EV / EBITDA - - - - - - - -
EV / FCF - - - - - -0.24 x -1.14 x -1.78 x
FCF Yield - - - - - -416% -87.6% -56.2%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 1,421 1,640 4,778 6,884 7,311 27,025 - -
Reference price 2 38.40 13.20 63.90 37.20 3.741 4.480 4.480 4.480
Announcement Date 19-06-25 20-06-29 21-06-29 22-06-23 23-06-28 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - 1.09 1.109 -0.2273 1.067 0.2 -
EBITDA - - - - - - - -
EBIT 1 -24.56 -20.8 -17.93 -47.78 -59.27 -32.36 -62.12 -65.49
Operating Margin - - -1,646.06% -4,308.68% 26,074.79% -3,033.23% -31,060.84% -
Earnings before Tax (EBT) 1 -24.59 -20.77 -17.93 -47.76 -59.24 -30.09 -61.79 -65.09
Net income 1 -25.73 -22.04 -42.32 -48.71 -59.25 -30.09 -61.79 -65.09
Net margin - - -3,884.33% -4,392.42% 26,065.86% -2,820.44% -30,894.16% -
EPS 2 -27.00 -15.00 -14.70 -7.500 -8.510 -1.598 -1.958 -1.550
Free Cash Flow 1 - - - - - -29 -53 -68
FCF margin - - - - - -2,718.54% -26,500% -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 19-06-25 20-06-29 21-06-29 22-06-23 23-06-28 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 0.358 0.3579 0.0389 0.3101 -0.8925 0.1796 0.1756 0.1776 0.2777 0.4114 0.2028 0.4 - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -12.8 -10.54 -16.69 -19.77 -17.49 -9.766 -12.24 -6.998 -6.78 -7.884 -10.7 -11.2 -15.8 -18.2 -19.4
Operating Margin -3,575.28% -2,945.01% -42,912.6% -6,376.36% 1,959.59% -5,437.92% -6,969.87% -3,940.2% -2,441.56% -1,916.38% -5,277.93% -2,800% - - -
Earnings before Tax (EBT) 1 -12.79 -10.54 -16.69 -19.77 -17.48 -9.761 -12.23 -6.901 -6.588 -6.35 -10.24 -11 -15.5 -17.9 -19.2
Net income 1 -13.17 -10.74 -16.69 -19.78 -17.48 -9.761 -12.23 -6.903 -6.588 -6.35 -10.24 -11 -15.5 -17.9 -19.2
Net margin -3,678.66% -3,001.73% -42,900.77% -6,377.39% 1,958.9% -5,434.97% -6,962.98% -3,886.88% -2,372.24% -1,543.46% -5,051.79% -2,750% - - -
EPS 2 -2.100 -1.500 -2.700 -3.000 -2.400 -1.500 -0.8433 -0.9400 -0.6600 -0.2200 -0.3625 -0.3700 -0.4900 -0.5600 -0.6350
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 21-11-10 22-02-10 22-06-23 22-08-11 22-11-10 23-02-07 23-06-28 23-08-10 23-11-09 24-02-13 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - - 114 60.6 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - -29 -53 -68
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 0.17 - 0.28 - - 0.5 0.34 0.2
Capex / Sales - - 25.28% - - 46.87% 170.5% -
Announcement Date 19-06-25 20-06-29 21-06-29 22-06-23 23-06-28 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.48 USD
Average target price
13.25 USD
Spread / Average Target
+195.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VISTAGEN THERAPEUTICS, INC. Stock Vistagen Therapeutics, Inc.
-14.59% 121M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.13% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.88% 104B
ARGENX SE Stock argenx SE
+1.28% 22.33B
BIONTECH SE Stock BioNTech SE
-12.78% 22.19B
GENMAB A/S Stock Genmab A/S
-7.05% 18.69B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.82% 17.64B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.21% 14.05B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.85% 12.51B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. Financials Vistagen Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW